In this context it has been recently shown that NSCLC patients with a high frequency of intratumor PD-1+ high CD8+ T cells and PD-L1+ high CD4+ Treg present a better clinical response during anti-PD-1 treatment [22,23]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.